Terms: = Brain cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
654 results:
1. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
3. Anti-PD-(L)1 plus braf/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of
Ramakrishnan D; Brüningk SC; von Reppert M; Memon F; Maleki N; Aneja S; Kazerooni AF; Nabavizadeh A; Lin M; Bousabarah K; Molinaro A; Nicolaides T; Prados M; Mueller S; Aboian MS
AJNR Am J Neuroradiol; 2024 Apr; 45(4):475-482. PubMed ID: 38453411
[TBL] [Abstract] [Full Text] [Related]
6. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
7. Promising response to vemurafenib and cobimetinib treatment for braf V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract] [Full Text] [Related]
8. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
Li J; Shih LK; Brat DJ
Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148
[TBL] [Abstract] [Full Text] [Related]
9. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
Gritsch D; Santagata S; Brastianos PK
Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
[TBL] [Abstract] [Full Text] [Related]
10. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract] [Full Text] [Related]
11. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M; Lorigan P; Sergi MC; Benannoune N; Serra P; Vitale MG; Giannarelli D; Arance AM; Couselo EM; Neyns B; Tucci M; Guida M; Spagnolo F; Rossi E; Occelli M; Queirolo P; Quaglino P; Depenni R; Merelli B; Placzke J; Di Giacomo AM; Del Vecchio M; Indini A; da Silva IP; Menzies AM; Long GV; Robert C; Rutkowski P; Ascierto PA
Eur J Cancer; 2024 Mar; 199():113542. PubMed ID: 38266540
[TBL] [Abstract] [Full Text] [Related]
12. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
13. Integrated proteogenomic characterization of glioblastoma evolution.
Kim KH; Migliozzi S; Koo H; Hong JH; Park SM; Kim S; Kwon HJ; Ha S; Garofano L; Oh YT; D'Angelo F; Kim CI; Kim S; Lee JY; Kim J; Hong J; Jang EH; Mathon B; Di Stefano AL; Bielle F; Laurenge A; Nesvizhskii AI; Hur EM; Yin J; Shi B; Kim Y; Moon KS; Kwon JT; Lee SH; Lee SH; Gwak HS; Lasorella A; Yoo H; Sanson M; Sa JK; Park CK; Nam DH; Iavarone A; Park JB
Cancer Cell; 2024 Mar; 42(3):358-377.e8. PubMed ID: 38215747
[TBL] [Abstract] [Full Text] [Related]
14. braf/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
[TBL] [Abstract] [Full Text] [Related]
15. Systemic Therapy for Melanoma brain and Leptomeningeal Metastases.
Sherman WJ; Romiti E; Michaelides L; Moniz-Garcia D; Chaichana KL; Quiñones-Hinojosa A; Porter AB
Curr Treat Options Oncol; 2023 Dec; 24(12):1962-1977. PubMed ID: 38158477
[TBL] [Abstract] [Full Text] [Related]
16. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
[TBL] [Abstract] [Full Text] [Related]
17. Systematic review and cumulative analysis of clinical properties of braf V600E mutations in PLNTY histological samples.
Baumgartner ME; Lang SS; Tucker AM; Madsen PJ; Storm PB; Kennedy BC
Childs Nerv Syst; 2024 May; 40(5):1361-1366. PubMed ID: 38150037
[TBL] [Abstract] [Full Text] [Related]
18. A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::braf fusion: a case report and literature review.
Zhang L; Zhang G; Zheng H; Jiang B; Ju Y; Duan Q; An L; Shi H
Brain Tumor Pathol; 2024 Jan; 41(1):18-29. PubMed ID: 38100030
[TBL] [Abstract] [Full Text] [Related]
19. Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial.
Ando Y; Shimoi T; Sunami K; Okita N; Nakamura K; Shibata T; Fujiwara Y; Yamamoto N
Cancer Sci; 2024 Feb; 115(2):555-563. PubMed ID: 38041215
[TBL] [Abstract] [Full Text] [Related]
20. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced braf V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
[Next]
